Since GLUT-4 is seen as one of the targets for therapeutic modalities and was significantly increased by OA, these findings are a significant step towards the better management and treatment of T2D and obesity [32]. This evidence concerns the gene SLC2A4 and obesity due to melanocortin 4 receptor deficiency.